This article is more than 5 years old. Information may no longer be current.

Alimera reports 86% increase in revenue in first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported net revenue of $3.9 million in the first quarter of 2015, an 86% increase from the first quarter of 2014. The increase was primarily attributed to $2.4 million in U.S. sales of Iluvien, according to a press release.

GAAP net loss applicable to common stockholders was reported at $9.8 million, or $0.22 per share, in the first quarter compared with $20.8 million, or $0.58 per share, in the first quarter of the previous year.

Research and development expenses were reported at $3.3 million in the first quarter compared with $2.8 million in the first quarter of the previous year. The increase was attributed to costs associated with the addition of U.S. medical sciences liaisons after the FDA approval of Iluvien (fluocinolone acetonide intravitreal implant), the release said.